Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03091192 · ClinicalTrials.gov registry record · Phase 3

Savolitinib vs. Sunitinib in MET-driven PRCC.

A Phase 3 study of Kidney Diseases and Carcinoma, Renal Cell, sponsored by AstraZeneca.

Active
Registry status
Phase 3
Development phase
60
Enrollment target
20
Study locations

NCT03091192 is a Phase 3 study of Kidney Diseases and Carcinoma, Renal Cell that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 60 participants, below the 1,784-participant average among 38 other Kidney Diseases trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03091192, a Phase 3 study of Kidney Diseases and Carcinoma, Renal Cell, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
60 participants
Enrollment target
20
Study locations

Study Summary

This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, how it compares with another medication frequently used to treat this disease called sunitinib, and what side effects it might cause.

Conditions Studied

Kidney Diseases Carcinoma, Renal Cell Carcinoma Neoplasms by Site Kidney Neoplasms Urologic Neoplasms Enzyme Inhibitors Protein Kinase Inhibitors

Interventions

  • DRUG Sunitinib
  • DRUG Savolitinib

Study Locations (20)

Other

  • Research Site - Barretos
  • Research Site - Curitiba
  • Research Site - Passo Fundo
  • Research Site - Pelotas
  • Research Site - Porto Alegre
  • Research Site - Porto Alegre
  • Research Site - Porto Alegre
  • Research Site - Rio de Janeiro
  • Research Site - São José do Rio Preto
  • Research Site - São Paulo
  • Research Site - São Paulo
  • Research Site - Bordeaux

California

  • Research Site - La Jolla

Georgia

  • Research Site - Atlanta

Illinois

  • Research Site - Chicago

Iowa

  • Research Site - Iowa City

Massachusetts

  • Research Site - Boston

Missouri

  • Research Site - Kansas City

New York

  • Research Site - New York

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2017-07-25
Est. Completion 2026-12-31
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03091192

The ClinicalTrials.gov registry entry for NCT03091192 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,784-participant average among 38 other Kidney Diseases trials with a reported enrollment target (97% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.

NCT03091192 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT03091192 about?

NCT03091192 is a clinical study titled "Savolitinib vs. Sunitinib in MET-driven PRCC.". This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is effective in treating patients with MET-driven PRCC, ho...

What is the current status of trial NCT03091192?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2017-07-25. Estimated completion is 2026-12-31.

What conditions does trial NCT03091192 study?

This clinical trial studies the following conditions: Kidney Diseases, Carcinoma, Renal Cell, Carcinoma, Neoplasms by Site, Kidney Neoplasms.

What interventions are being tested in trial NCT03091192?

The interventions under investigation include: Sunitinib (DRUG), Savolitinib (DRUG).

Who is sponsoring clinical trial NCT03091192?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03091192 being conducted?

This trial has 20 study locations across California, Georgia, Illinois, Iowa, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Kidney Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Kidney Diseases

All registered trials for this condition

Carcinoma, Renal Cell

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.